Bausch Health patented a method for delivering drugs using cationic linear polyphosphazenes with hydrophilic poly(ethylene glycol) and spacer groups. The polyphosphazene-drug conjugates show high tumor selectivity and low toxicity. GlobalData’s report on Bausch Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bausch Health Companies Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bausch Health, Cancer treatment biomarkers was a key innovation area identified from patents. Bausch Health's grant share as of February 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.

Drug delivery method using polyphosphazene-drug conjugates

Source: United States Patent and Trademark Office (USPTO). Credit: Bausch Health Companies Inc

A recently granted patent (Publication Number: US11912829B2) discloses a method for delivering drugs to patients or living objects in need thereof. The method involves administering linear polyphosphazene-drug conjugate compounds represented by a specific chemical formula. The compounds include a spacer group (S) which can be lysine or a lysine-containing dipeptide or tripeptide. Additionally, the compounds contain a hydrophobic molecule (D) selected from docetaxel, paclitaxel, camptothecin, and (dach)Pt(II) (dach: trans±1,2-diaminocyclohexane).

The patent further elaborates on the chemical formulas and variations within the compounds, specifying different expressions and configurations. It emphasizes the importance of the spacer group (S) and the hydrophobic molecule (D) in the effectiveness of drug delivery. By utilizing these specific linear polyphosphazene-drug conjugate compounds, the method aims to enhance the targeted delivery of drugs to patients or living objects in need, potentially improving treatment outcomes and reducing side effects associated with traditional drug administration methods.

To know more about GlobalData’s detailed insights on Bausch Health, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies